Logo

Innovent Reports First Patient Dosing in P-II Clinical Trial of Mazdutide for the Treatment of Obesity in Chinese Adults

Share this

Innovent Reports First Patient Dosing in P-II Clinical Trial of Mazdutide for the Treatment of Obesity in Chinese Adults

Shots:

  • The first patient has been dosed in the higher-dose cohort of a P-II trial to evaluate mazdutide vs PBO in a ratio (3:1) in 90 Chinese patients with overweight or obesity
  • The trial met its 1EPs i.e., low-dose mazdutide showed a significant efficacy on body weight loss in a dose-dependent manner @24wk. & multiple cardio-metabolic benefits to patients were well tolerated and the overall safety profile was similar to other drugs
  • In the P-Ib study, mazdutide titrated to 9mg had a good safety profile & a 12wk. body weight loss of 11.7%. The effectiveness & safety of mazdutide at a higher dose of 9.0mg will be further assessed by Innovent while patients with obesity will have a safer, more convenient & comparable therapy alternative with higher-dose mazdutide

Ref: PR Newswire | Image: Innovent 

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions